D3ZBP4

SS
Gene name
Mical1
Protein name
[F-actin]-monooxygenase MICAL1
Names
Molecule interacting with CasL protein 1, MICAL-1
Species
Rattus norvegicus (Rat)
KEGG Pathway
rno:294520
EC number
1.6.3.1: With oxygen as acceptor
Protein Class

Descriptions

MICAL1 (molecule interacting with CasL) is a multidomain cytosolic protein with a putative flavoprotein monooxygenase region required for semaphorin-plexin repulsive axon guidance. The C-terminal domain of MICAL1 inhibit its enzymatic activity. Plexin binding to the C terminus disrupts the interaction of MICAL1 C terminus with the enzymatic domain, releasing autoinhibition and leading to the activation of the monooxygenase activity. Truncation of the C-terminal region (761-1048) relieves autoinhibition of MICAL.

Autoinhibitory domains (AIDs)

759-1047 (C-terminal autoinhibitory region) SS

Target domain

1-489 (FAD-binding domain)

Relief mechanism

Partner binding

Assay

Accessory elements

No accessory elements

References

Autoinhibited structure

Activated structure

1 structures for D3ZBP4

Entry ID Method Resolution Chain Position Source
AF-D3ZBP4-F1 Predicted AlphaFoldDB

No variants for D3ZBP4

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for D3ZBP4

12 associated diseases with D3ZBP4

[MIM: 131440]: Myeloproliferative disorder chronic with eosinophilia (MPE)

A hematologic disorder characterized by malignant eosinophils proliferation. . Note=The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving ETV6 is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with PDGFRB on chromosome 5 creating an ETV6-PDGFRB fusion protein. .

[MIM: 601626]: Leukemia, acute myelogenous (AML)

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. . Note=The gene represented in this entry is involved in disease pathogenesis.

[MIM: 616216]: Thrombocytopenia 5 (THC5)

A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC5 is an autosomal dominant disorder, associated with an increased susceptibility to the development of hematologic and solid malignancies. . Note=The disease is caused by variants affecting the gene represented in this entry.

Without disease ID
  • A hematologic disorder characterized by malignant eosinophils proliferation. . Note=The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving ETV6 is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with PDGFRB on chromosome 5 creating an ETV6-PDGFRB fusion protein. .
  • A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. . Note=The gene represented in this entry is involved in disease pathogenesis.
  • A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC5 is an autosomal dominant disorder, associated with an increased susceptibility to the development of hematologic and solid malignancies. . Note=The disease is caused by variants affecting the gene represented in this entry.

7 regional properties for D3ZBP4

Type Name Position InterPro Accession
domain VHS domain 5 - 146 IPR002014
domain GAT domain 171 - 299 IPR004152
domain Clathrin adaptor, alpha/beta/gamma-adaptin, appendage, Ig-like subdomain 595 - 719 IPR008152
domain Gamma-adaptin ear (GAE) domain 598 - 719 IPR008153
domain N-terminal extension of GAT domain 169 - 207 IPR041198
domain GGA3, GAT domain 213 - 299 IPR044111
domain GGA3, VHS domain 6 - 146 IPR046996

Functions

Description
EC Number 1.6.3.1 With oxygen as acceptor
Subcellular Localization
  • Cytoplasm
  • Cytoplasm, cytoskeleton
  • Endosome membrane
  • Midbody
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

5 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytoskeleton A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles.
hippocampal mossy fiber expansion Synaptic expansion of hippocampal mossy fiber axon that makes contact with the thorny excrescences of hippocampal CA3 pyramidal cell dendrites.
intercellular bridge A direct connection between the cytoplasm of two cells that is formed following the completion of cleavage furrow ingression during cell division. They are usually present only briefly prior to completion of cytokinesis. However, in some cases, such as the bridges between germ cells during their development, they become stabilised.
midbody A thin cytoplasmic bridge formed between daughter cells at the end of cytokinesis. The midbody forms where the contractile ring constricts, and may persist for some time before finally breaking to complete cytokinesis.

9 GO annotations of molecular function

Name Definition
actin binding Binding to monomeric or multimeric forms of actin, including actin filaments.
FAD binding Binding to the oxidized form, FAD, of flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes.
metal ion binding Binding to a metal ion.
monooxygenase activity Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water.
NAD(P)H oxidase H2O2-forming activity Catalysis of the reaction: NAD(P)H + H+ + O2 = NAD(P)+ + hydrogen peroxide.
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from NADH or NADPH and one other donor, and one atom of oxygen is incorporated into one donor.
protein kinase binding Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.
SH3 domain binding Binding to a SH3 domain (Src homology 3) of a protein, small protein modules containing approximately 50 amino acid residues found in a great variety of intracellular or membrane-associated proteins.
small GTPase binding Binding to a small monomeric GTPase.

6 GO annotations of biological process

Name Definition
actin filament depolymerization Disassembly of actin filaments by the removal of actin monomers from a filament.
negative regulation of apoptotic process Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process Any process that stops, prevents, or reduces the frequency, rate or extent of a cysteine-type endopeptidase activity involved in the apoptotic process.
negative regulation of protein phosphorylation Any process that stops, prevents or reduces the rate of addition of phosphate groups to amino acids within a protein.
regulation of regulated secretory pathway Any process that modulates the frequency, rate or extent of regulated secretory pathway.
sulfur oxidation The chemical reactions and pathways resulting the addition of oxygen to elemental sulfur.

6 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
F1MH07 MICAL1 [F-actin]-monooxygenase MICAL1 Bos taurus (Bovine) SS
Q9BT23 LIMD2 LIM domain-containing protein 2 Homo sapiens (Human) PR
Q8TDZ2 MICAL1 [F-actin]-monooxygenase MICAL1 Homo sapiens (Human) EV
Q8BGB5 Limd2 LIM domain-containing protein 2 Mus musculus (Mouse) PR
Q9ERG0 Lima1 LIM domain and actin-binding protein 1 Mus musculus (Mouse) PR
Q8VDP3 Mical1 [F-actin]-monooxygenase MICAL1 Mus musculus (Mouse) EV
10 20 30 40 50 60
MASPTSTNPA HDHFETFVQA QLCQDVLSSF QGLCRALGVE SGGGLPQYHK IKAQLNYWSA
70 80 90 100 110 120
KSLWAKLDKR ASQPAYQQGQ ACTNTKCLVV GAGPCGLRAA VELALLGARV VLVEKRTKFS
130 140 150 160 170 180
RHNVLHLWPF TIHDLRALGA KKFYGRFCTG TLDHISIRQL QLLLLKVALL LGVEIHWGFT
190 200 210 220 230 240
FTGLQPPPKK GSGWRARIQP SPPAQLASYE FDVLISAGGG KFVPEGFTIR EMRGKLAIGI
250 260 270 280 290 300
TANFVNGRTV EETQVPEISG VARIYNQKFF QSLLKATGID LENIVYYKDD THYFVMTAKK
310 320 330 340 350 360
QCLLRLGVLR QDLPETDQLL GKANVVPEAL QQFARAAADF ATQGKLGKLE FAQDARGRPD
370 380 390 400 410 420
VAAFDFTSMM RSESSARIQE KHGARLLLGL VGDCLVEPFW PLGTGVARGF LAAFDAAWMV
430 440 450 460 470 480
KRWAEGTGPL ELLAERESLY QLLSQTSPEN MHRNVAQYGL DPATRYPNLN LRAVTPNQVQ
490 500 510 520 530 540
DLYDIMDKEH ARKKSDETDA RKTTTGSAGT EELLHWCQEQ TAGFPGVSVT DFSSSWADGR
550 560 570 580 590 600
ALCALVHRLQ PGLLEPSELQ GMSALEATAW ALRVAEYELG IIPVLSAQAV VAGSDPLGLI
610 620 630 640 650 660
AYLSHFHSAF KNTPHSSGLV SQPHGTPSAI LFLGKLQRSL QRTRTKVEEE TPCTEEPPVS
670 680 690 700 710 720
EPSVPPALPS EHEEAGAEDV CELCGKRLYI LERFCVDGHF FHRGCFCCRT CEATLRPGGY
730 740 750 760 770 780
GQYPGDGYFY CLQHLPQEDQ KEADNNGSPE NQELPTPGDS TTQSGPSSPV PPVTEASPVP
790 800 810 820 830 840
SPSQPARRLI RLSSVERLRL SSLNIIPDSG VEPPPKPPRS CLDLAQESLK SSFMGWGVLR
850 860 870 880 890 900
APQVPEAIEK GEEEEEEEEE EEEEEEELPP PLALEVEQSL LTLAKNSGDM TKYPTWRRTL
910 920 930 940 950 960
MRRAKEEEMK RFCKAQAIQR RLNEIEAAMR ELETEGMKLE VALRKESSSP EKQKKLWLEQ
970 980 990 1000 1010 1020
LLQLIQKKNS LVTEEAELMI TVQELDLEEK QRQLDHEFRG INREETLKTQ ADRLSEDRVL
1030 1040
RKLLDVVNQR DALIQFQEER RLREMPV